Biomolecules · 2026
Sequence evidence
CYGSR
CYGSR
Experimental observations
The IC50 of L-CR5 was calculated as 377.83 ± 34.32 μg/mL (646.25 ± 58.70 μM). Figure 3 caption: IC50 = 377.83 ± 34.32 μg/mL; (646.25 ± 58.70 μM), n = 3.
The scavenging ability of L-CR5 gradually increased from 18% to 53% in the range of 25–400 μg/mL.
The scavenging ability of L-CR5 gradually increased from 18% to 53% in the range of 25–400 μg/mL.
IC50 of L-CR5 was calculated as 377.83 ± 34.32 μg/mL (646.25 ± 58.70 μM).
The IC50 of L-CR5 was calculated as 680.63 ± 15.68 μg/mL (1164.0 ± 27.3 μM). Figure 4 caption: IC50 = 680.63 ± 15.68 μg/mL; (1164.0 ± 27.3 μM), n = 3.
IC50 of L-CR5 was calculated as 680.63 ± 15.68 μg/mL (1164.0 ± 27.3 μM).
In the range of 50–800 μg/mL, the tyrosinase inhibitory rate of L-CR5 gradually increased from 1.16% to 57.35%.
In the range of 50–800 μg/mL, the tyrosinase inhibitory rate of L-CR5 gradually increased from 1.16% to 57.35%.
L-CR5 showed expression levels of 99–100% in the 25–100 μg/mL range, had little tendency to decrease, and no significant inhibitory effect was observed at 100.80% even at 200 and 400 μg/mL.
As a result of treating the RAW 264.7 macrophages with L-CR5 and C-CR5 at a concentration of 6.25–400 μg/mL, cell viability was maintained at 95% or more in all treatment groups.
Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.
